About ANGIOMAX

Breadth of Clinical Data and Experience1

Unsurpassed ischemic efficacy throughout the risk spectrum in patients
undergoing PCI

ACS=acute coronary syndromes; CAD=coronary artery disease;
PTCA=percutaneous transluminal angioplasty; UA=unstable angina.

More than 1.25 million patients have been treated with ANGIOMAX since 2001.9-11

Potent efficacy demonstrated in clinical trials involving nearly 25,000 patients1-5

ANGIOMAX has been given a Class I recommendation in the following national ACC/AHA guidelines:12-14

Safety Considerations
ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (≥10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.

1ANGIOMAX Prescribing Information. The Medicines Company; Parsippany, NJ, December 6, 2005.

2Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.

3Bittl JA, Chaitman BR, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-959.

4Stone GW, White HD, Ohman EM, et al; for the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Lancet. 2007;369:907-919.

5Stone GW, Witzenbichler B, Guagliumi G, et al; for the HORIZONS AMI trial investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.

6Fuster V, Badimon L, Badimon JJ, Chesebro JH. Mechanisms of disease: the pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.

7Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med. 2000;342:101-114.

8Rich JD, Maraganore JM, Young E, et al. Heparin resistance in acute coronary syndromes. J Thromb Thrombolysis. 2007;23:93-100.

9Data on file. The Medicines Company; Parsippany, NJ.

10Source® Non-retail Database, 2002-2007. Conshohocken, Pa: Wolters Kluwer Health.

11ACTracker® Database, 2007. Evanston, Ill: Solucient, LLC.

12Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary. Circulation. 2007;116:803-877.

13Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. Circulation. 2008;117:296-329.

14King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation. 2008;117:261-295.

© 2008 The Medicines Company
Acute Care Hospital Products
NASDAQ: MDCO